Login / Signup

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.

Timothy Anthony YapAnthony W TolcherRuth PlummerJatinder Kaur MukkerMarta EnderlinChristine HickingThomas GrombacherGiuseppe LocatelliZoltan SzucsIoannis GounarisJohann S de Bono
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tuvusertib demonstrated manageable safety and exposure-related target engagement. Further clinical evaluation of tuvusertib is ongoing.
Keyphrases
  • endothelial cells
  • dna damage
  • social media
  • randomized controlled trial
  • early onset
  • open label